
GENY Biologics
GENY Biologics Pte Ltd develops first-in-class diagnostics and biologic drugs for infectious diseases and cancer, exploiting a full suite of advanced antibody discovery and engineering technologies and an AI algorithm for identification of novel cancer targets. Its value proposition is a unique discovery platform which employs a powerful, trade secreted method to screen the complete human repertoire of memory B cells from convalescent patients with infectious diseases, using high-throughput functional assays and a bioinformatics approach to identify and sequence the antibodies responsible for resolving the infection.
Antibodies derived from this platform are biologically functional, their clinical relevance already proven, because the patient recovered. These “super-antibodies” display extremely high affinity, low immunogenicity and are of immense commercial value because their human origin means they benefit from millions of years of evolution; the natural processes that take place in the human body generates by far the most diverse range of antibodies possible, through clonal selection and affinity maturation, to generate the human repertoire which is, and will remain, unrivalled by any other discovery platform, including humanized mice, with its more limited repertoire, or any antibody generated from synthetic libraries or by other means.
GENY’s lead candidates are the first ever dengue treatment, currently in preclinical development at Lonza Biologics, and a range of serotype-specific anti-dengue antibodies under development as a companion diagnostic that can accurately determine the serotype of dengue infection, distinguishing it from other highly similar flaviviruses.
For further enquiry, please contact Mary Kozma via email or mobile number: +65 9731 9701